Search
Ultragenyx Pharmaceutical Inc
RAREAdd to Watchlist
32.847USD
-0.543-1.63%
Market hours （ET）Quotes delayed by 15 min
3.23BMarket Cap
LossP/E TTM
More Details of Ultragenyx Pharmaceutical Inc Company
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
Ultragenyx Pharmaceutical Inc Info
Ticker SymbolRARE
Company nameUltragenyx Pharmaceutical Inc
IPO dateJan 31, 2014
CEOKakkis (Emil D)
Number of employees1294
Security typeOrdinary Share
Fiscal year-endJan 31
Address60 Leveroni Ct
CityNOVATO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94949
Phone14154838800
Websitehttps://www.ultragenyx.com/
Ticker SymbolRARE
IPO dateJan 31, 2014
CEOKakkis (Emil D)
Company Executives of Ultragenyx Pharmaceutical Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.83M
+2.71%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
140.45K
+16.46%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
90.60K
+31.89%
Mr. Howard Horn
Mr. Howard Horn
Chief Financial Officer, Executive Vice President, Corporate Strategy
Chief Financial Officer, Executive Vice President, Corporate Strategy
44.07K
-10.56%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
34.70K
+22.34%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
34.70K
+22.34%
Dr. Amrit Ray, M.D.
Dr. Amrit Ray, M.D.
Independent Director
Independent Director
25.38K
+30.54%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
22.21K
+9.05%
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Mr. John R. Pinion, II
Mr. John R. Pinion, II
Chief Quality Officer, Executive Vice President - Translational Sciences
Chief Quality Officer, Executive Vice President - Translational Sciences
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.83M
+2.71%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
140.45K
+16.46%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
90.60K
+31.89%
Mr. Howard Horn
Mr. Howard Horn
Chief Financial Officer, Executive Vice President, Corporate Strategy
Chief Financial Officer, Executive Vice President, Corporate Strategy
44.07K
-10.56%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
34.70K
+22.34%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
34.70K
+22.34%
FAQs
Who are the top five shareholders of Ultragenyx Pharmaceutical Inc?
The top five shareholders of Ultragenyx Pharmaceutical Inc are: Dr. Emil D. Kakkis, M.D., Ph.D.
How many institutions hold shares of Ultragenyx Pharmaceutical Inc (RARE)?
As of 2026Q1, 695 institutions hold shares of Ultragenyx Pharmaceutical Inc, with a combined market value of approximately 106.19M, accounting for 107.82% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -1315399.00.
What is the biggest source of revenue for Ultragenyx Pharmaceutical Inc?
In 2026Q1, the Crysvita royalty revenue business generated the highest revenue for Ultragenyx Pharmaceutical Inc, amounting to 304.00M and accounting for 45.17% of total revenue.